JINARC 60 MG
TOLVAPTAN : 60 MG TOLVAPTAN : 30 MG · DIN 02437511 · OTSUKA PHARMACEUTICAL CO LTD
Health Canada status: MARKETED
What is JINARC?
JINARC 60 MG contains TOLVAPTAN : 60 MG TOLVAPTAN : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02437511, held by OTSUKA PHARMACEUTICAL CO LTD, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Jun-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02437511 |
|---|---|
| Brand name | JINARC |
| Generic / active ingredient | TOLVAPTAN : 60 MG TOLVAPTAN : 30 MG |
| Manufacturer | OTSUKA PHARMACEUTICAL CO LTD |
| Strength | 60 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03XA01 TOLVAPTAN |
| AHFS class | 40:28.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Jun-2015 |
| Original market date | 2015-06-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C03XA01 TOLVAPTAN. 10 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JINARC | 15 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02437503 |
| JINARC | 15 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02491575 |
| JINARC | 90 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02437538 |
| JINARC | Strength | Tablet | OTSUKA PHARMACEUTICAL CO LTD 2-9 Kanda-Tsukasamachi Chiyoda-Ku Tokyo -- Japan 101-8535 | MARKETED | DIN 02491583 |
| LUPIN-TOLVAPTAN | 15 MG | TABLET | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02557177 |
| LUPIN-TOLVAPTAN | 30 MG | TABLET | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02557185 |
| LUPIN-TOLVAPTAN | 90 MG | TABLET | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02557215 |
| SAMSCA | 15 MG | Tablet | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02370468 |
| SAMSCA | 30 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02370476 |
| SAMSCA | 60 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | APPROVED | DIN 02370484 |
Who else supplies TOLVAPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TOLVAPTAN appears in 113 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.